ArticleFrontiers in neuroscience2025
A method for measuring first glymphatic influx of a cerebrospinal fluid tracer in the human brain.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The glymphatic system is a brain-wide perivascular transport route for fluids and solutes in which cerebrospinal fluid (CSF) serves as a conduit for solute transport and clearance of brain waste. Intrathecal contrast-enhanced magnetic resonance imaging (MRI), where the intrathecal contrast agent serves as a CSF tracer, has been developed to measure glymphatic function in humans. The normalized MRI T1 signal is a semiquantitative measure of CSF flow and exchange with the brain. Objective: To estimate first-time tracer appearance within brain tissue after intrathecal tracer injection. Methods: This study implemented segmented regression analysis to estimate the first-time tracer appearance of an intrathecal tracer within brain tissues. An increase (breakpoint) in the normalized MRI T1 signal was defined to represent first glymphatic influx of the tracer. The study included 30 reference (REF) subjects with no identified CSF disturbance and 15 patients with a diagnosis of idiopathic intracranial hypertension (IIH). We developed and evaluated the method in REF subjects and further compared it between the two study groups. Results: The time to initial glymphatic tracer enrichment in the REF cohort was approximately 1 h in the frontal, temporal, parietal, and occipital cerebral cortex and ranged from two to 4 h in the corresponding white matter regions. In subcortical limbic structures and basal ganglia structures, it was 0.6 and 2.2 h, respectively. Compared with REF subjects, IIH patients presented a non-significant mean difference in the first appearance of ±0.5 h in the cerebral cortex and white matter regions, with somewhat longer estimated delays in the parietal and insular white matter regions. The results are presented as time series plots and estimates with 95% confidence intervals. Additionally, we provide supplementary R code, which can be adapted for use in future studies, and outline a basic assessment of true versus estimated breakpoints using simulated data. Conclusion: Segmented regression was found feasible to quantify the time to first glymphatic enrichment, i.e., increase in the normalized MRI T1 signal. Moreover, the method seems reasonable to differentiate first glymphatic influx between the cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.